관류 시스템 시장 규모, 점유율, 동향 분석 보고서 : 용도별, 지역별, 부문별 예측(2024-2030년)

Perfusion Systems Market Growth & Trends:

The global perfusion systems market size is projected to reach USD 1.55 billion by 2030, according to a new report by Grand View Research, Inc. Furthermore, the market is projected to advance at a CAGR of 4.8% from 2024 to 2030. Factors such as the growing prevalence of chronic diseases and the rise in the number of organ transplants and multiple organ failures are anticipated to boost the market growth. In addition, increasing investments in cell-based research and a rise in biologics manufacturing are further expected to impel the growth of the perfusion system industry.

There was a steep downfall in the sales of perfusion systems during the first half of the pandemic. The lockdowns and restrictions imposed by governments globally resulted in reduced patient visits to hospitals, a reduced number of surgeries, and a slowdown in R&D activities. However, with the increasing efforts of the government and healthcare professionals to curb the spread of the virus and prepare for similar events in the future, the market began to recover in 2021 and is expected to flourish during the forecast period.

Perfusion Systems Market Report Highlights:

• Based on application, the perfusion systems market is segmented into cardiopulmonary perfusion system, cell perfusion system, and ex-vivo organ perfusion system. The cardiopulmonary perfusion system dominated the market in 2023 due to the high prevalence of cardiac diseases globally
• In terms of region, North America accounted for the highest market share in 2023. The rising incidences of chronic disorders, a well-established healthcare sector, and a rise in the number of organ donors are driving the regional market growth
• The COVID-19 pandemic had a significant negative impact on the market for perfusion systems. Factors such as the change in healthcare priorities, social distancing, and global lockdowns resulted in a reduced number of surgeries and a fall in the number of organ donations and transplants
• The coronavirus outbreak led to a decline in the sales of perfusion systems; however, post the first wave of the pandemic, the market recovered and is expected to reach its pre-COVID growth level during the forecast period

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation and Scope
  • 1.1.1 Segment Definitions
  • 1.1.2. Application
  • 1.1.3. Regional scope
  • 1.1.4. Estimates and forecasts timeline
• 1.2. Research Methodology
• 1.3. Information Procurement
  • 1.3.1. Purchased database
  • 1.3.2. GVR's internal database
  • 1.3.3. Secondary sources
  • 1.3.4. Primary research
  • 1.3.5. Details of primary research
    • 1.3.5.1. Data for primary interviews in North America
    • 1.3.5.2. Data for primary interviews in Europe
    • 1.3.5.3. Data for primary interviews in Asia Pacific
    • 1.3.5.4. Data for primary interviews in Latin America
    • 1.3.5.5. Data for Primary interviews in MEA
• 1.4. Information or Data Analysis
  • 1.4.1. Data analysis models
• 1.5. Market Formulation & Validation
• 1.6. Model Details
  • 1.6.1. Commodity flow analysis (Model 1)
  • 1.6.2. Approach 1: Commodity flow approach
  • 1.6.3. Volume price analysis (Model 2)
  • 1.6.4. Approach 2: Volume price analysis
• 1.7. List of Secondary Sources
• 1.8. List of Primary Sources
• 1.9. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
  • 2.2.1. Application outlook
• 2.3. Regional outlook
• 2.4. Competitive Insights

Chapter 3. Perfusion Systems Market Variables, Trends & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent Market Outlook
  • 3.1.2. Related/ancillary market outlook
• 3.2. Market Dynamics
  • 3.2.1. Market Driver Analysis
    • 3.2.1.1. Increasing prevalence of cardiovascular and respiratory diseases
    • 3.2.1.2. Rising number of organ transplantations
    • 3.2.1.3. Growth in aging population and increasing incidence of multiple organ failures
    • 3.2.1.4. Government and NGO initiatives to encourage organ donation
    • 3.2.1.5. Increasing investments in cell-based research
    • 3.2.1.6. Rise in biologic manufacturing
  • 3.2.2. Market Restraint Analysis
    • 3.2.2.1. High cost of organ transplantation
    • 3.2.2.2. Ethical concerns and high cost of cell-based research
• 3.3. Perfusion Systems Market Analysis Tools
  • 3.3.1. Industry Analysis - Porter's Five Forces
    • 3.3.1.1. Bargaining power of suppliers
    • 3.3.1.2. Bargaining power of buyers
    • 3.3.1.3. Threat of substitutes
    • 3.3.1.4. Threat of new entrants
    • 3.3.1.5. Competitive rivalry
  • 3.3.2. PESTEL Analysis
    • 3.3.2.1. Political landscape
    • 3.3.2.2. Economic landscape
    • 3.3.2.3. Social landscape
    • 3.3.2.4. Technological landscape
    • 3.3.2.5. Environmental landscape
    • 3.3.2.6. Legal landscape

Chapter 4. Perfusion systems Market: Application Estimates & Trend Analysis

• 4.1. Segment Dashboard
• 4.2. Perfusion Systems Market: Application Movement Analysis
• 4.3. Perfusion Systems Market by Application Outlook (USD Million)
• 4.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
• 4.5. Cardiopulmonary Perfusion System
  • 4.5.1. Cardiopulmonary Perfusion System Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.5.2. Oxygenators
    • 4.5.2.1. Oxygenators Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.5.3. Heart-Lung Machine
    • 4.5.3.1. Heart-Lung Machine Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.5.4. Perfusion Pumps
    • 4.5.4.1. Perfusion Pumps Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.5.5. Cannula
    • 4.5.5.1. Cannula Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.5.6. Monitoring System
    • 4.5.6.1. Monitoring System Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.5.7. Others
    • 4.5.7.1. Others Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 4.6. Cell Perfusion System
  • 4.6.1. Cell Perfusion System Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.6.2. Bioreactor Perfusion System
    • 4.6.2.1. Bioreactor Perfusion System Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.6.3. Microfluidic Perfusion System
    • 4.6.3.1. Microfluidic Perfusion System Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.6.4. Gravity/Pressure-driven Perfusion System
    • 4.6.4.1. Gravity/Pressure-driven Perfusion System Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.6.5. Small Mammal Organ Perfusion System
    • 4.6.5.1. Small Mammal Organ Perfusion System Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 4.7. Ex-Vivo Organ Perfusion System
  • 4.7.1. Ex-Vivo Organ Perfusion System Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.7.2. Hypothermic
    • 4.7.2.1. Hypothermic Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.7.3. Normothermic
    • 4.7.3.1. Normothermic Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 5. Perfusion Systems Market: Regional Estimates & Trend Analysis

• 5.1. Regional Dashboard
• 5.2. Regional Perfusion systems Market movement analysis
• 5.3. Perfusion systems Market: Regional Estimates & Trend Analysis by Technology & End-use
• 5.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
• 5.5. North America
  • 5.5.1. North America Perfusion Systems Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.5.2. U.S.
    • 5.5.2.1. Key Country Dynamics
    • 5.5.2.2. Competitive Scenario
    • 5.5.2.3. Regulatory Framework
    • 5.5.2.4. Reimbursement scenario
    • 5.5.2.5. U.S. Perfusion Systems Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.5.3. Canada
    • 5.5.3.1. Key Country Dynamics
    • 5.5.3.2. Competitive Scenario
    • 5.5.3.3. Regulatory Framework
    • 5.5.3.4. Reimbursement scenario
    • 5.5.3.5. Canada Perfusion Systems Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.5.4. Mexico
    • 5.5.4.1. Key Country Dynamics
    • 5.5.4.2. Competitive Scenario
    • 5.5.4.3. Regulatory Framework
    • 5.5.4.4. Reimbursement scenario
    • 5.5.4.5. Mexico Perfusion Systems Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 5.6. Europe
  • 5.6.1. Europe Perfusion Systems Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.6.2. UK
    • 5.6.2.1. Key Country Dynamics
    • 5.6.2.2. Competitive Scenario
    • 5.6.2.3. Regulatory Framework
    • 5.6.2.4. Reimbursement scenario
    • 5.6.2.5. UK Perfusion Systems Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.6.3. Germany
    • 5.6.3.1. Key Country Dynamics
    • 5.6.3.2. Competitive Scenario
    • 5.6.3.3. Regulatory Framework
    • 5.6.3.4. Reimbursement scenario
    • 5.6.3.5. Germany Perfusion Systems Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.6.4. France
    • 5.6.4.1. Key Country Dynamics
    • 5.6.4.2. Competitive Scenario
    • 5.6.4.3. Regulatory Framework
    • 5.6.4.4. Reimbursement scenario
    • 5.6.4.5. France Perfusion Systems Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.6.5. Italy
    • 5.6.5.1. Key Country Dynamics
    • 5.6.5.2. Competitive Scenario
    • 5.6.5.3. Regulatory Framework
    • 5.6.5.4. Reimbursement scenario
    • 5.6.5.5. Italy Perfusion Systems Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.6.6. Spain
    • 5.6.6.1. Key Country Dynamics
    • 5.6.6.2. Competitive Scenario
    • 5.6.6.3. Regulatory Framework
    • 5.6.6.4. Reimbursement scenario
    • 5.6.6.5. Spain Perfusion Systems Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.6.7. Denmark
    • 5.6.7.1. Key Country Dynamics
    • 5.6.7.2. Competitive Scenario
    • 5.6.7.3. Regulatory Framework
    • 5.6.7.4. Reimbursement scenario
    • 5.6.7.5. Denmark Perfusion Systems Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.6.8. Sweden
    • 5.6.8.1. Key Country Dynamics
    • 5.6.8.2. Competitive Scenario
    • 5.6.8.3. Regulatory Framework
    • 5.6.8.4. Reimbursement scenario
    • 5.6.8.5. Sweden Perfusion Systems Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.6.9. Norway
    • 5.6.9.1. Key Country Dynamics
    • 5.6.9.2. Competitive Scenario
    • 5.6.9.3. Regulatory Framework
    • 5.6.9.4. Reimbursement scenario
    • 5.6.9.5. Norway Perfusion Systems Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 5.7. Asia Pacific
  • 5.7.1. Asia Pacific Perfusion Systems Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.7.2. Japan
    • 5.7.2.1. Key Country Dynamics
    • 5.7.2.2. Competitive Scenario
    • 5.7.2.3. Regulatory Framework
    • 5.7.2.4. Reimbursement scenario
    • 5.7.2.5. Japan Perfusion Systems Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.7.3. China
    • 5.7.3.1. Key Country Dynamics
    • 5.7.3.2. Competitive Scenario
    • 5.7.3.3. Regulatory Framework
    • 5.7.3.4. Reimbursement scenario
    • 5.7.3.5. China Perfusion Systems Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.7.4. India
    • 5.7.4.1. Key Country Dynamics
    • 5.7.4.2. Competitive Scenario
    • 5.7.4.3. Regulatory Framework
    • 5.7.4.4. Reimbursement scenario
    • 5.7.4.5. India Perfusion Systems Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.7.5. South Korea
    • 5.7.5.1. Key Country Dynamics
    • 5.7.5.2. Competitive Scenario
    • 5.7.5.3. Regulatory Framework
    • 5.7.5.4. Reimbursement scenario
    • 5.7.5.5. South Korea Perfusion Systems Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.7.6. Australia
    • 5.7.6.1. Key Country Dynamics
    • 5.7.6.2. Competitive Scenario
    • 5.7.6.3. Regulatory Framework
    • 5.7.6.4. Reimbursement scenario
    • 5.7.6.5. Australia Perfusion Systems Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.7.7. Thailand
    • 5.7.7.1. Key Country Dynamics
    • 5.7.7.2. Competitive Scenario
    • 5.7.7.3. Regulatory Framework
    • 5.7.7.4. Reimbursement scenario
    • 5.7.7.5. Thailand Perfusion Systems Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 5.8. Latin America
  • 5.8.1. Latin America Perfusion Systems Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.8.2. Brazil
    • 5.8.2.1. Key Country Dynamics
    • 5.8.2.2. Competitive Scenario
    • 5.8.2.3. Regulatory Framework
    • 5.8.2.4. Reimbursement scenario
    • 5.8.2.5. Brazil Perfusion Systems Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.8.3. Argentina
    • 5.8.3.1. Key Country Dynamics
    • 5.8.3.2. Competitive Scenario
    • 5.8.3.3. Regulatory Framework
    • 5.8.3.4. Reimbursement scenario
    • 5.8.3.5. Argentina Perfusion Systems Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 5.9. Middle East & Africa
  • 5.9.1. Middle East & Africa Perfusion Systems Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.9.2. South Africa
    • 5.9.2.1. Key Country Dynamics
    • 5.9.2.2. Competitive Scenario
    • 5.9.2.3. Regulatory Framework
    • 5.9.2.4. Reimbursement scenario
    • 5.9.2.5. South Africa Perfusion Systems Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.9.3. Saudi Arabia
    • 5.9.3.1. Key Country Dynamics
    • 5.9.3.2. Competitive Scenario
    • 5.9.3.3. Regulatory Framework
    • 5.9.3.4. Reimbursement scenario
    • 5.9.3.5. Saudi Arabia Perfusion Systems Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.9.4. UAE
    • 5.9.4.1. Key Country Dynamics
    • 5.9.4.2. Competitive Scenario
    • 5.9.4.3. Regulatory Framework
    • 5.9.4.4. Reimbursement scenario
    • 5.9.4.5. UAE Perfusion Systems Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.9.5. Kuwait
    • 5.9.5.1. Key Country Dynamics
    • 5.9.5.2. Competitive Scenario
    • 5.9.5.3. Regulatory Framework
    • 5.9.5.4. Reimbursement scenario
    • 5.9.5.5. Kuwait Perfusion Systems Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 6. Competitive Landscape

• 6.1. Market Participant Categorization
• 6.2. Key Company Profiles
  • 6.2.1. Getinge
    • 6.2.1.1. Company overview
    • 6.2.1.2. Financial performance
    • 6.2.1.3. Product benchmarking
    • 6.2.1.4. Strategic initiatives
  • 6.2.2. Medtronic, plc
    • 6.2.2.1. Company overview
    • 6.2.2.2. Financial performance
    • 6.2.2.3. Product benchmarking
    • 6.2.2.4. Strategic initiatives
  • 6.2.3. LivaNova PLC
    • 6.2.3.1. Company overview
    • 6.2.3.2. Financial performance
    • 6.2.3.3. Product benchmarking
    • 6.2.3.4. Strategic initiatives
  • 6.2.4. Terumo Corporation
    • 6.2.4.1. Company overview
    • 6.2.4.2. Financial performance
    • 6.2.4.3. Product benchmarking
    • 6.2.4.4. Strategic initiatives
  • 6.2.5. Nipro Corporation
    • 6.2.5.1. Company overview
    • 6.2.5.2. Financial performance
    • 6.2.5.3. Product benchmarking
    • 6.2.5.4. Strategic initiatives
  • 6.2.6. Fresenius SE & Co. KGaA (XENIOS AG)
    • 6.2.6.1. Company overview
    • 6.2.6.2. Financial performance
    • 6.2.6.3. Product benchmarking
    • 6.2.6.4. Strategic initiatives
  • 6.2.7. Repligen Corporation
    • 6.2.7.1. Company overview
    • 6.2.7.2. Financial performance
    • 6.2.7.3. Product benchmarking
    • 6.2.7.4. Strategic initiatives
  • 6.2.8. Spectrum Medical
    • 6.2.8.1. Company overview
    • 6.2.8.2. Financial performance
    • 6.2.8.3. Product benchmarking
    • 6.2.8.4. Strategic initiatives
  • 6.2.9. Merck KGaA
    • 6.2.9.1. Company overview
    • 6.2.9.2. Financial performance
    • 6.2.9.3. Product benchmarking
    • 6.2.9.4. Strategic initiatives
  • 6.2.10. Harvard Bioscience, Inc.
    • 6.2.10.1. Company overview
    • 6.2.10.2. Financial performance
    • 6.2.10.3. Product benchmarking
    • 6.2.10.4. Strategic initiatives
  • 6.2.11. Lifeline Scientific
    • 6.2.11.1. Company overview
    • 6.2.11.2. Financial performance
    • 6.2.11.3. Product benchmarking
    • 6.2.11.4. Strategic initiatives
  • 6.2.12. ALA Scientific Instruments, Inc.
    • 6.2.12.1. Company overview
    • 6.2.12.2. Financial performance
    • 6.2.12.3. Product benchmarking
    • 6.2.12.4. Strategic initiatives
  • 6.2.13. XVIVO Perfusion AB
    • 6.2.13.1. Company overview
    • 6.2.13.2. Financial performance
    • 6.2.13.3. Product benchmarking
    • 6.2.13.4. Strategic initiatives